MetaCap

Aardvark Therapeutics Inc. (AARD)

NASDAQ: AARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.9226-0.0774 (-7.74%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AARD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$20.20M
EPS (TTM)
-$3.33
52-week range
0.90 – 16.60
Day range
0.90 – 1.06
Volume / Avg
241.07K / 643.53K
Beta
—

52-week range

$0.90$16.60

AARD stock today

Aardvark Therapeutics (AARD) closed at $0.9226 on Nov 20, down 7.74% (-$0.0774), versus the S&P 500's 3.70% decline. Trading was light, with 241.07K shares changing hands, about 37% of the average daily volume. At this level, AARD sits near the bottom of its 52-week range of $0.90 to $16.60: 94.4% below the high, set on Jan 22, 2026 and 2.5% above the low.

AARD is down 93.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 90.2%. Aardvark Therapeutics has posted a net loss over the last twelve months (EPS of -$3.33), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aardvark Therapeutics

Company profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Tien-Li Lee M.D.
Headquarters
San Diego, CA
Employees
28
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Aardvark Therapeutics generated $0 in revenue. Aardvark Therapeutics reported a net loss of $57.6 million, compared with a loss of $20.6 million a year earlier. Diluted earnings per share came in at -$2.93.

Aardvark Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$0—
Growth——
Net income$-57.59M$-20.59M
EPS (diluted)$-2.93$-5.15

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$11.11+1104.21%

  • Strong buy 0
  • Buy 6
  • Hold 4
  • Sell 1
  • Strong sell 1

Target range

Low $3.00High $28.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.75 vs $-0.69
Surprise
-8.70%

AARD news

All AARD news

Aardvark Therapeutics peers

Health Care sector
AARD peer companies
CompanyPrice% ChgMarket capCompare
RNAZTransCode Therapeutics Inc.1.16-10.77%$20.07Mvs AARD
ACETAdicet Bio Inc.2.14-13.01%$20.03Mvs AARD
TXMDTherapeuticsMD Inc.1.71-5.52%$19.79Mvs AARD
IGCIGC Pharma Inc.0.168-8.70%$19.60Mvs AARD
CPHIChina Pharma Holdings Inc.0.4384-13.00%$18.86Mvs AARD
CRVOCervoMed Inc.1.46+9.77%$22.09Mvs AARD
COCPCocrystal Pharma Inc.0.95-2.05%$18.30Mvs AARD
MRKRMarker Therapeutics Inc.1.09-17.42%$18.17Mvs AARD

Indexes, lists and sector

Aardvark Therapeutics stock FAQ

What is Aardvark Therapeutics's stock price today?

AARD last traded at $0.9226 as of Nov 20, 4:00 PM EST, down 7.74% on the day. Prices are delayed at least 15 minutes.

Who is Aardvark Therapeutics's CEO?

Dr. Tien-Li Lee M.D. is the chief executive officer of Aardvark Therapeutics Inc., which has about 28 employees.

What is the AARD 52-week high?

The 52-week high for AARD is $16.60 and the 52-week low is $0.90. The stock is currently 94.4% below its high.

Compare AARD